Mandate

Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care

August 26, 2010

Vinge is advising Investor AB (publ) in connection with Investor’s agreement with Morgan Stanley Principal Investments to acquire Morgan Stanley’s 34 per cent equity stake in Mölnlycke Health Care Group AB. The purchase price amounts to EUR 510 million and following the transaction Investor will hold a 96 per cent equity stake. The remaining shares will be owned by Mölnlycke’s management and board.

Mölnlycke is a world leading manufacturer and provider of single-use surgical and wound care products and services, primarily for the professional healthcare sector. Investor together with Morgan Stanley originally invested in Mölnlycke in 2007.

Vinge’s team advising Investor consists of Ola Sandersson, Pontus Enquist, Dain Nevonen and Fredrik von der Esch. Johan Karlsson and Peter Alstegren are providing competiton law advice. Hans Wibom is the client relationship partner.

Related

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023

Vinge has advised private equity firm Stirling Square Capital Partners

Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023

Vinge advises Stendörren in connection with issuance of green notes and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 500 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued notes due 2024.
September 21, 2023